Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses

Molecular Immunology

Volumn 48, Issue 6-7, 2011, Pages 810-817

  de Vries, I Jolanda M ^a   Tel, Jurjen ^a   Benitez Ribas, Daniel ^a   Torensma, Ruurd ^a   Figdor, Carl G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CpG oligonucleotides; Immune response; Plasmacytoid dendritic cells; TOLL receptors; Vaccines

Indexed keywords

ALPHA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS A VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; TYPHOID VACCINE; YELLOW FEVER VACCINE;

CELL MATURATION; DENDRITIC CELL; DRUG ACTIVITY; DRUG COST; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INTERFERON PRODUCTION; PRIORITY JOURNAL; REVIEW;

CHLOROQUINE; DENDRITIC CELLS; HUMANS; IMMUNITY; OLIGODEOXYRIBONUCLEOTIDES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; VACCINES;

EID: 79951554765     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.12.022     Document Type: Review

References (38)

1. Angel J., Cooper C., Clinch J., Young C., Chenier A., Parato K., Lautru M., Davis H., Cameron D. CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. J. Immune Based Ther. Vaccines 2008, 6(1):4.
2. Barchet W., Wimmenauer V., Schlee M., Hartmann G. Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr. Opin. Immunol. 2008, 20(4):389-395.
3. Benitez-Ribas D., Adema G.J., Winkels G., Klasen I.S., Punt C.J., Figdor C.G., de Vries I.J. Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake. J. Exp. Med. 2006, 203(7):1629-1635.
4. Benitez-Ribas D., Tacken P.J., Punt C.J., de Vries I.J.M., Figdor C.G. Activation of human plasmacytoid dendritic cells by TLR9 impairs Fcgamma-mediated uptake of immune complexes and presentation by MHC class II. J. Immunol. 2008, 181(8):5219-5224.
5. Bhattacharjee R.N., Akira S. Modifying toll-like receptor 9 signaling for therapeutic use. Mini Rev. Med. Chem. 2006, 6(3):287-291.
6. Corey D.R. Chemical modification: the key to clinical application of RNA interference?. J. Clin. Invest. 2007, 117(12):3615-3622.
7. da Fonseca D.M., Silva C.L., Wowk P.F., Paula M.O., Ramos S.G., Horn C., Marchal G., Bonato V.L. Mycobacterium tuberculosis culture filtrate proteins plus CpG oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion. Infect. Immun. 2009, 77(12):5311-5321.
8. de Vries I.J., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen M.J., Croockewit S., Britten C.M., Torensma R., Adema G.J., Figdor C.G., Punt C.J. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 2003, 9(14):5091-5100.
9. Germi R., Crance J.M., Garin D., Guimet J., Lortat-Jacob H., Ruigrok R.W., Zarski J.P., Drouet E. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 2002, 292(1):162-168.
10. Goubier A., Dubois B., Gheit H., Joubert G., Villard-Truc F., Asselin-Paturel C., Trinchieri G., Kaiserlian D. Plasmacytoid dendritic cells mediate oral tolerance. Immunity 2008, 29(3):464-475.
11. Guiducci C., Ott G., Chan J.H., Damon E., Calacsan C., Matray T., Lee K.D., Coffman R.L., Barrat F.J. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J. Exp. Med. 2006, 203(8):1999-2008.
12. Hartmann G., Battiany J., Poeck H., Wagner M., Kerkmann M., Lubenow N., Rothenfusser S., Endres S. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur. J. Immunol. 2003, 33(6):1633-1641.
13. Hemmi H., Akira S. TLR signalling and the function of dendritic cells. Chem. Immunol. Allergy 2005, 86:120-135.
14. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408(6813):740-745.
15. Janeway C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 1989, 54 Pt 1:1-13.
16. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., Lipford G., Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 2002, 3(6):499.
17. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., Liu Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001, 194(6):863-869.
18. Kaisho T., Akira S. Critical roles of Toll-like receptors in host defense. Crit. Rev. Immunol. 2000, 20(5):393-405.
19. Kaisho T., Akira S. Regulation of dendritic cell function through Toll-like receptors. Curr. Mol. Med. 2003, 3(4):373-385.
20. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007, 13(5):552-559.
21. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., Tsujimura T., Takeda K., Fujita T., Takeuchi O., Akira S. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23(1):19-28.
22. Kerkmann M., Rothenfusser S., Hornung V., Towarowski A., Wagner M., Sarris A., Giese T., Endres S., Hartmann G. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 2003, 170(9):4465-4474.
23. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709-760.
24. Krieg A.M. From A to Z on CpG. Trends Immunol. 2002, 23(2):64-65.
25. Krieg A.M. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 2007, 117(5):1184-1194.
26. Krieg A.M., Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol. Rev. 2007, 220:251-269.
27. Latz E., Schoenemeyer A., Visintin A., Fitzgerald K.A., Monks B.G., Knetter C.F., Lien E., Nilsen N.J., Espevik T., Golenbock D.T. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 2004, 5(2):190-198.
28. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12:991-1045.
29. Montoya C.J., Jie H.B., Al-Harthi L., Mulder C., Patino P.J., Rugeles M.T., Krieg A.M., Landay A.L., Wilson S.B. Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. J. Immunol. 2006, 177(2):1028-1039.
30. Pulendran B. Tolls and beyond-many roads to vaccine immunity. N. Engl. J. Med. 2007, 356(17):1776-1778.
31. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 2009, 9(10):741-747.
32. Pulendran B., Tang H., Denning T.L. Division of labor, plasticity, and crosstalk between dendritic cell subsets. Curr. Opin. Immunol. 2008, 20(1):61-67.
33. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., Akira S., Ahmed R., Pulendran B. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 2006, 203(2):413-424.
34. Schmidt M., Raghavan B., Muller V., Vogl T., Fejer G., Tchaptchet S., Keck S., Kalis C., Nielsen P.J., Galanos C., Roth J., Skerra A., Martin S.F., Freudenberg M.A., Goebeler M. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat. Immunol. 2010, 11(9):814-819.
35. Schreibelt G., Benitez-Ribas D., Schuurhuis D., Lambeck A.J.A., van Hout-Kuijer M., Schaft N., Punt C.J.A., Figdor C.G., Adema G.J., de Vries I.J.M. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 2010, 116(4):564-574.
36. Sugiyama T., Gursel M., Takeshita F., Coban C., Conover J., Kaisho T., Akira S., Klinman D.M., Ishii K.J. CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+monocytes. J. Immunol. 2005, 174(4):2273-2279.
37. Trieu A., Roberts T.L., Dunn J.A., Sweet M.J., Stacey K.J. DNA motifs suppressing TLR9 responses. Crit. Rev. Immunol. 2006, 26(6):527-544.
38. Wang X., Bao M., Wan M., Wei H., Wang L., Yu H., Zhang X., Yu Y., Wang L. A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine. Vaccine 2008, 26(15):1893-1901.